HypoxemiaGastric Cancer (Diagnosis)Chronic Obstructive Pulmonary Disease (COPD)Esophageal Cancer
Investigational drug(s) / intervention(s)
High-flow nasal cannula
High-flow nasal cannula: Using high-flow nasal cannula oxygenation
Study summary
Hypoxemia is the most common adverse event during propofol sedation for gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD) due to diminished pulmonary reserve. Although high-flow nasal cannula (HFNC) oxygenation has been shown to effectively reduce hypoxemia during sedated endoscopy in obese patients, its application in COPD patients remains an evidence gap, largely owing to the traditional concern that high-concentration oxygen may suppress respiratory drive and exacerbate CO₂ retention. This study aims to investigate whether HFNC can reduce the incidence of hypoxemia during sedated gastrointestinal endoscopy in patients with COPD.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years;
* Confirmed diagnosis of chronic obstructive pulmonary disease (COPD);
* Scheduled for elective sedated gastroenteroscopy (gastroscopy, colonoscopy, or combined gastroscopy and colonoscopy);
* Expected procedure duration ≤45 minutes;
* Provision of written informed consent by the participant.
Exclusion Criteria:
* Patients with absolute contraindications to high-flow therapy, including but not limited to confirmed diagnosis of complete upper airway obstruction, basilar skull fracture or nasal bone fracture, pneumothorax, or pneumomediastinum.;
* American Society of Anesthesiologists (ASA) Physical Status class ≥ IV;
* Requirement for planned endotracheal intubation;
* Existing tracheostomy;
* Confirmed pregnancy or currently breastfeeding;
* Known allergy to sedative agents such as propofol;
* Current participation in another interventional clinical trial;
* Any other condition deemed by the investigator to make the patient unsuitable for trial participation.
Primary outcome measure(s)
The incidence of hypoxemia — Patients will be followed for the duration of hospital stay, an expected average about 2 hours 75% ≤ SpO2 \< 90% for \<60 s
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital, Zhejiang University School of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.